Explore every approved treatment, every open clinical trial, and every option your doctor might not know to mention — all in plain English, all in one place. Browse anonymously. No account required.
You're likely here because you — or someone you love — is navigating a cancer diagnosis and trying to figure out what comes next. Maybe you've already spent hours searching and found nothing but statistics that terrified you and jargon written for doctors. That's exactly what this site was built to fix.
Your Cancer Path guides you through the full journey — starting with our Diagnostic Path, which walks you step by step through what tests should happen and in what order before any treatment begins. From there, our Care Pathways show how oncologists sequence treatment decisions, and our live clinical trial search surfaces every actively recruiting study matched to your cancer type. All of it in plain English. No hype. No agenda. Just facts.
This is not a substitute for your oncologist. But it will help you walk into that office better informed, with better questions, and a clearer picture of every option on the table. That's all we're trying to do.
Select a cancer type below to explore every approved treatment, open clinical trial, and promising investigational drug — in plain English.
Browse every cancer type above, or use the Explore page to find treatments, open trials, and promising drugs for any diagnosis.
I'm a prostate cancer survivor, and I built this because I lost a close friend to cancer last November — and spent months before that trying to help him find options the system never surfaced for him.
Clinical trials he qualified for. Expanded Access programs that were open and waiting. A drug the manufacturer was willing to provide. The information existed. We just couldn't get to it in time.
Your Cancer Path is my answer to that. Free. Anonymous. No agenda. Everything I wish we'd had — all in one place, in plain English, for every patient who deserves to walk into their next appointment knowing every option on the table.
Every treatment, side effect, and efficacy rate is sourced from FDA approvals, peer-reviewed studies, and ClinicalTrials.gov. We cite everything. This site is primarily U.S.-focused — international visitors should verify approval status with their local regulatory authority.
Browse everything without creating an account. No email required. No tracking. Your health search is your business alone.
Every open, enrolling clinical trial pulled directly from ClinicalTrials.gov — filtered, simplified, and explained in plain English.
Our community is moderated by cancer survivors who've been through it. Every post is reviewed before publishing. Real experiences, verified.
Enter your city to find actively enrolling trials near you. Results come directly from ClinicalTrials.gov — broader than the curated list below.
These are drugs that have shown meaningful results in clinical trials but have not yet received full FDA approval. They may be available through clinical trial enrollment, compassionate use, or Right to Try. All data is factual and sourced from published trial results.
Care pathways show the typical sequence of treatment decisions — from first-line options through salvage and escalation if earlier treatments stop working. These reflect how oncologists generally think about sequencing, not a prescription for any individual patient. Always discuss your specific situation with your care team.
Select a cancer type to explore every approved treatment, open clinical trial, and promising investigational drug.
Live data pulled from ClinicalTrials.gov. Every trial listed is actively recruiting. Search by cancer type or keyword below.
Most patients who qualify never find out about trials they're eligible for. Your Cancer Path was built to change that. Reading this page is the first step.
Enter your city to find actively enrolling trials within your area. Optionally filter by cancer type, drug name, or company. Results pull directly from ClinicalTrials.gov and include contact information for each site.
Scores and assessments your oncologist uses — explained in plain English so you can understand what they mean for your care.
Clinical scores like ECOG are assigned by your oncologist based on direct observation — not self-report alone. Use these calculators to understand what the scores mean and to have better conversations with your care team, not to make treatment decisions independently.
The Right to Try Act (2018) and the FDA's Expanded Access program give seriously ill patients legal pathways to access investigational drugs that are not yet approved. Here's exactly how to pursue them — with real contacts, real forms, and real steps.
This guide is for informational and educational purposes only. It is not legal or medical advice. Your Cancer Path strongly recommends consulting with your oncologist and, where appropriate, a healthcare attorney before pursuing any of these pathways. Laws, eligibility requirements, and manufacturer policies vary by situation and may change.
The Right to Try Act and FDA Expanded Access programs described on this page are U.S.-specific legal pathways. Health Canada administers the Special Access Program (SAP). The European Medicines Agency (EMA) and individual EU member states have their own compassionate use frameworks. Australia's TGA offers the Special Access Scheme. Please speak with an oncologist in your country about locally available pathways.
| Pathway | Who Approves | Timeline | Best For |
|---|---|---|---|
| Clinical Trial | IRB + FDA (ongoing) | Weeks to enroll | Best option if eligible — structured monitoring, no cost |
| Expanded Access EAP | Manufacturer + FDA | Days to weeks | Drug has an open EAP program — contact sponsor directly |
| Individual Expanded Access | Manufacturer + FDA (Form 3926) | Days (24 hrs emergency) | No open EAP — physician submits individual request to FDA |
| Right to Try | Manufacturer only (no FDA) | Varies by company | Exhausted all options, cannot do clinical trial or EAP |
These are manufacturer-sponsored programs that are currently open and accepting patients. Unlike clinical trials, EAPs don't require competitive enrollment — you contact the sponsor directly. This list is updated as programs are added to the site. Always verify current status directly with the sponsor before proceeding.
If you are a patient, caregiver, or sponsor with an open Expanded Access Program that should be listed here, contact us. We verify all listings against ClinicalTrials.gov or official FDA records before publishing. Our goal is to maintain the most complete and accurate EAP directory for cancer patients in the US.
If there is no open EAP for the drug you need, your physician can submit an individual patient Expanded Access request directly to the FDA. The FDA approves approximately 99% of these requests. For oncology, the dedicated Project Facilitate team can help your physician through the process within days.
Individual Expanded Access is for patients with a serious or immediately life-threatening condition for whom no comparable or satisfactory alternative therapy exists. Your physician must document that approved treatments have been tried or are not appropriate, and that you cannot participate in a clinical trial for this drug.
Before submitting anything to the FDA, the drug manufacturer must agree to provide the drug. Your physician contacts the manufacturer's Medical Affairs or Compassionate Use department and requests a Letter of Authorization (LOA). This letter allows the FDA to reference the manufacturer's existing IND (Investigational New Drug application) — which means your physician doesn't need to submit all the underlying drug safety data. Without an LOA, the process is significantly more complex.
To find the manufacturer's Medical Affairs contact: search the drug name on navigator.reaganudall.org — the Reagan-Udall Foundation's Expanded Access Navigator includes a Company Directory with contact information for most manufacturers.
Once the manufacturer provides an LOA, your physician submits FDA Form 3926 (Individual Patient Expanded Access — Investigational New Drug Application) along with the LOA to the FDA's dedicated oncology team. This is the form specifically designed for individual patient expanded access requests and is easier to complete than the standard IND forms.
Most expanded access requests require Institutional Review Board (IRB) review. However, Form 3926 includes a checkbox (Field 10.b) that allows your physician to request that IRB review be conducted by a single designated IRB member rather than the full committee — significantly speeding up the process. In emergency situations, treatment can begin before IRB review if the IRB is notified within 5 business days.
Once the FDA completes its review — typically within days for non-emergency requests, 24 hours for emergencies — it issues a letter to your treating physician confirming the Expanded Access IND is approved and treatment may proceed. After informed consent is obtained, treatment can begin. Your physician will need to submit a summary of the treatment outcomes to the FDA at conclusion, and annual reports during ongoing treatment.
Right to Try is a federal law that bypasses the FDA entirely — the request goes directly to the manufacturer. The tradeoff is less oversight and no FDA safety review. Most oncology access advocates recommend trying FDA Expanded Access first, as it provides more structure and support. Right to Try is best used when FDA Expanded Access has been declined or is not available for a specific drug.
Under the Right to Try Act, you must: (a) have a life-threatening diagnosis confirmed by a licensed physician; (b) have tried all approved treatment options or be unable to participate in a clinical trial; (c) be unable to enroll in a clinical trial for the specific drug. Your physician must certify all of this in writing. The drug must have completed at least Phase 1 safety testing and be in active clinical development.
No FDA involvement is required — the request goes directly to the drug manufacturer's Medical Affairs or Compassionate Use department. The Reagan-Udall Expanded Access Navigator (navigator.reaganudall.org) has a Company Directory with contact information. Be prepared to explain your diagnosis, treatment history, and why you are seeking this specific drug.
The manufacturer will require a letter from your treating physician confirming your diagnosis, prior treatment history, and clinical rationale for the request. Your physician must agree to monitor your treatment and document outcomes. Manufacturers are not required to provide the drug under Right to Try — but many will, particularly if you are a well-documented case that adds safety data to their ongoing program.
Insurance typically does not cover Right to Try drugs. The manufacturer may provide the drug at no cost, at cost, or at compassionate pricing — policies vary significantly by company and situation. Ask the manufacturer explicitly about compassionate pricing and patient assistance. Some patient advocacy organizations can help fund access. Key resources: Patient Advocate Foundation 1-800-532-5274 · HealthWell Foundation 1-800-675-8416 · PAN Foundation 1-866-316-7263.
Many oncologists are unfamiliar with Expanded Access mechanics. Some may be hesitant. This is a reasonable conversation to initiate — your oncologist is your partner in this process and the FDA's Project Facilitate team is specifically designed to help physicians who have not done this before.
Share your journey. Read others. Ask questions. Every post is reviewed by a volunteer moderator — a cancer survivor — before it goes live. You are not alone.
These rules exist to protect every person in this community. Please read them fully before participating.
Your Cancer Path is a research, education, and peer support platform for cancer patients, survivors, caregivers, and their families. It is not a medical practice, does not provide medical advice, and is not a substitute for consultation with a licensed physician or oncologist.
All information on Your Cancer Path is intended to help users become more informed participants in their own healthcare decisions — not to replace professional medical judgment.
All users — whether browsing anonymously or with an account — agree to the following standards when interacting with Your Cancer Path:
All posts submitted to Your Cancer Path go into a moderation queue before becoming publicly visible. Posts are reviewed by trained volunteer moderators — all of whom are cancer survivors or caregivers with lived experience.
Automated Red Flag System: Our platform uses keyword and pattern detection to pre-categorize posts:
Treatment information, clinical trial data, drug efficacy figures, and side effect profiles published by Your Cancer Path on its treatment and trial pages are sourced exclusively from:
Your Cancer Path does not publish editorial opinions on treatment effectiveness. Where data conflicts between sources, we note the conflict and cite all sources. All content pages display their last review date and data source.
Users who create an account and opt in to trial matching agree to the following:
Volunteer moderators agree to additional standards:
Your Cancer Path provides educational guides on Right to Try and FDA Expanded Access. This content is:
Your Cancer Path does not facilitate or arrange drug access on behalf of any user. We provide information to help patients advocate for themselves in partnership with their treating physician.
By accessing or using Your Cancer Path (the "Platform"), whether as an anonymous visitor, registered user, community member, volunteer moderator, or any other capacity, you ("User") agree to be bound by these Terms of Service ("Terms"), our Privacy Policy, and our Community Rules, all of which are incorporated herein by reference.
If you do not agree to these Terms in their entirety, you must immediately discontinue use of the Platform. Your Cancer Path reserves the right to modify these Terms at any time. Continued use of the Platform following notice of modification constitutes acceptance of the revised Terms.
The Your Cancer Path name, compass rose logo, tagline "Find Clarity. Move Forward.", platform design, source code, written content, community guidelines, treatment data organization and presentation methodology, trial matching system, and all other original content on the Platform are the exclusive intellectual property of Your Cancer Path and its founder, Kelly Foy, protected by United States and international copyright, trademark, and trade secret laws.
User-submitted content (posts, comments, testimonials) remains the intellectual property of the submitting user. By submitting content to the Platform, you grant Your Cancer Path a perpetual, worldwide, royalty-free, non-exclusive license to use, display, reproduce, and distribute such content in connection with operating and promoting the Platform, including in anonymized and aggregated research and marketing materials.
[ATTORNEY NOTE: Confirm DMCA safe harbor compliance, counter-notification procedures, and designated agent registration with Copyright Office.]
Your Cancer Path collects the following categories of information:
Your Cancer Path treats all health-related user data as protected health information (PHI) and implements HIPAA-compliant administrative, physical, and technical safeguards. We do not sell your personal data. We do not share your personal contact information with pharmaceutical sponsors or any third party without your explicit consent. Sponsors may contact opted-in users only through the Platform's internal messaging system.
You have the right to access, correct, export, and delete your personal data at any time through your account settings. Requests can also be submitted to [email protected].
[ATTORNEY NOTE: Review full CCPA compliance requirements for California users, including opt-out rights, data deletion timelines, and annual disclosure obligations. Confirm HIPAA covered entity vs. business associate status. Prepare full Privacy Policy as a separate document.]
The trial matching and opt-in contact feature operates as follows:
[ATTORNEY NOTE: Review FDA regulations on patient recruitment advertising (21 C.F.R. Part 312), FTC endorsement guidelines, and state-specific patient brokering laws. Confirm sponsor vetting standards and contractual requirements for platform access.]
Your Cancer Path does not warrant that:
To the maximum extent permitted by applicable law, Your Cancer Path, its founder, officers, advisors, moderators, and affiliates shall not be liable for any indirect, incidental, special, consequential, punitive, or exemplary damages arising from your use of or inability to use the Platform, including but not limited to medical decisions made in reliance on Platform content, loss of data, or unauthorized access to your account.
Your Cancer Path's total cumulative liability to you for any claim arising from these Terms or your use of the Platform shall not exceed the greater of: (a) the total fees paid by you to Your Cancer Path in the twelve months preceding the claim, or (b) one hundred dollars ($100.00).
[ATTORNEY NOTE: Confirm enforceability of liability cap under California law. Review consumer protection statutes that may limit disclaimer enforceability for health-related platforms.]
You agree to indemnify, defend, and hold harmless Your Cancer Path, its founder Kelly Foy, medical advisors, volunteer moderators, employees, contractors, and agents from and against any claims, liabilities, damages, losses, costs, and expenses (including reasonable attorneys' fees) arising out of or related to: (a) your use of the Platform; (b) your violation of these Terms; (c) your violation of any third-party rights, including intellectual property, privacy, or publicity rights; (d) any content you submit to the Platform; or (e) any medical decision you make based on information found on the Platform.
These Terms shall be governed by the laws of the State of California without regard to conflict of law principles. Any dispute arising from or relating to these Terms or your use of the Platform shall be resolved by binding arbitration administered by the American Arbitration Association under its Consumer Arbitration Rules, except that either party may seek injunctive or other equitable relief in any court of competent jurisdiction to protect intellectual property or confidential information.
[ATTORNEY NOTE: Review enforceability of mandatory arbitration and class action waiver under California law, including PAGA claims for employees. Confirm AAA Consumer Arbitration Rules are appropriate and that filing fees do not create unconscionability concerns.]
Your Cancer Path is an interactive computer service as defined under 47 U.S.C. § 230 (the Communications Decency Act). Your Cancer Path is not the publisher or speaker of user-generated content posted by community members and is not liable for such content to the extent permitted by Section 230. Your Cancer Path's moderation activities, including reviewing, approving, rejecting, or removing content, do not constitute editorial control that would eliminate Section 230 protections.
However, Your Cancer Path does not rely solely on Section 230 as a shield. We proactively moderate all content before publication to protect our community, and we will cooperate with law enforcement and regulatory authorities in response to lawful requests regarding Platform content.
[ATTORNEY NOTE: Confirm current Section 230 jurisprudence in the Ninth Circuit and any pending legislative changes. Review whether health-specific platforms face additional exposure under state consumer protection or health information statutes.]
Your Cancer Path accepts voluntary donations and Founding Member fees to support platform operations. All financial transactions are processed through third-party payment processors. Your Cancer Path does not store payment card information.
[ATTORNEY NOTE: Review IRS regulations on charitable solicitation, state charitable solicitation registration requirements (many states require registration before soliciting donations), and FTC endorsement rules for testimonials used in fundraising.]
All legal notices, attorney correspondence, DMCA takedown requests, privacy requests, and general inquiries should be directed to:
Your Cancer Path will respond to properly submitted legal notices within 10 business days. For urgent matters involving user safety or potential harm, please indicate "URGENT" in your subject line.
Last Updated: April 2026 (Pre-Launch Draft — Pending Attorney Review)
Effective Date: Upon public launch (TBD)
Version: 1.0 MVP Draft
These Terms, Community Rules, and Privacy Policy collectively constitute the complete legal framework governing use of Your Cancer Path. Your Cancer Path reserves the right to update these documents at any time. Users will be notified of material changes via email (registered users) and platform banner notice (all users).
Treatments and trials you've starred. Saved to this device — no account needed.
"I've had my own experience with cancer. Years ago I faced a diagnosis that shook my world and opened my eyes to how hard it is to navigate the medical system when you're scared and don't know what questions to ask. I survived. I consider myself one of the lucky ones. But it was losing a close friend to cancer this past November that became the real catalyst behind Your Cancer Path."
He was someone I genuinely liked and admired — we first crossed paths in the 1990s, and when I found out about his diagnosis, something in me just couldn't stand by. I was determined to help him find every option available — not just the standard path, but everything. Clinical trials. Experimental drugs. Expanded Access. Right to Try. I believed then, and I believe now, that there were options worth exploring that might have given him more time.
What I found instead was a wall — not built by any one person, but by a system with layers of complexity that most patients and families have no idea exist.
He went through chemotherapy. He tried a targeted radiation therapy that made him miserable — the side effects were severe, and there were stretches where he was essentially confined to home because of how his body responded. He lost feeling in his feet. He was exhausted and in pain. And through all of it, he kept fighting.
I worked closely with him and his wife. I went to doctor's appointments with them. I tried to help navigate a path toward an investigational drug — one the manufacturer was willing and ready to provide. The drug company said yes. There was no guarantee it would have worked. But we wanted the chance to try.
What we ran into was the reality of how complex these pathways are. The paperwork. The liability concerns. The way our medical system is structured around standard of care — for reasons that aren't always wrong, but that can leave patients without options when time is short. His physician had real concerns, including around malpractice coverage, and I came to understand that those concerns are part of a bigger, broken system — not a reflection of any one doctor's heart. But in the moment, it felt like a door closing.
His wife didn't know these pathways existed. My friend didn't know. Most people don't — because nobody tells them. I reached out to physicians across the country trying to find someone who could help us move forward. A few pointed us in directions that required steps we couldn't complete in time.
My friend fought with everything he had. In the end, the cancer spread to his brain, his lungs, his entire body. He passed away in November. He is out of pain now. But I carry the weight of knowing that information and access existed that he never got to — and that we just couldn't connect him to it in time.
Your Cancer Path exists because of him. It exists for the patient who was just diagnosed and doesn't yet know what the road ahead might look like — what the diagnostic process involves, what questions to ask, and what options exist before treatment even begins. It exists for the patient already in treatment who wonders whether there is something else worth trying. It exists so that every patient — and their spouse, and their family — walks into every appointment knowing every option on the table. So they know what a clinical trial is and how to find one. So they know what Expanded Access means and how to start that conversation with their doctor. So they know that if one door closes, there may be others worth knocking on. I am not a doctor. This platform is not medical advice. But it is here, and it is free, and no one should have to navigate this alone.
To put factual, comprehensive, plain-English cancer treatment information in the hands of every patient and family who needs it — free, anonymous, and without agenda — so they can have better conversations with their doctors and find the right path faster.
Your Cancer Path is independently operated. Pharma sponsors pay to reach our opted-in community — they do not pay to shape what we publish. Every fact is cited. Every source is disclosed. Our medical advisory board reviews all clinical content independently.
Your Cancer Path operates as two connected entities: Your Cancer Path Inc. (the tech company that builds and maintains the platform) and Your Cancer Path Foundation (the nonprofit that funds free access for patients who can't afford anything). Founding Memberships and Build Faster contributions go to the tech company. Fund a Fighter donations go directly to the nonprofit foundation. Full financial transparency is published quarterly.
Processed securely via Stripe. Receipt emailed automatically.
One-time payment. No subscriptions. No hidden fees. Transferable to family members.
Goes to Your Cancer Path Inc. (the tech company). Supports platform operations and growth.
Your Cancer Path is currently in beta. Whether you're a patient, caregiver, medical professional, or potential partner — we'd love to stay in touch as we build toward full launch.
The content on Your Cancer Path has not yet been reviewed by a licensed medical professional. All information is sourced from the FDA, ClinicalTrials.gov, and peer-reviewed publications, but please treat this as a starting point for conversations with your oncologist — not a substitute for professional medical advice.
Fill out the form below and we'll be in touch. We read every submission personally.
Review each post against community standards. Approve, reject, or escalate. You are not evaluating medical accuracy — only compliance with community rules.